IKT

+ Watchlist + Portfolio

Inhibikase Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.45
52-Week Range: $1.33 – $2.53
Market Cap: $327.91M
P/E (TTM): —
EPS (TTM): -0.44
Dividend Yield: —

Advanced Metrics

Price/Book: 2.68
PEG Ratio: —
Return on Equity: -51.96%
Return on Assets: -32.79%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 15.82
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-22.10M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $267.04M

IKT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$12.03M	$13.62M	$17.21M	$29.79M
Selling, General & Admin	$6.22M	$6.73M	$11.38M	$23.56M
Operating Expenses	$18.13M	$20.09M	$28.59M	$53.35M
Operating Income	-$18.13M	-$20.09M	-$28.59M	-$53.35M
EBITDA	-$18.12M	-$19.91M	-$28.56M	-$53.29M
Pretax Income	-$18.05M	-$19.03M	-$27.52M	-$48.26M
Net Income	-$18.05M	-$19.03M	-$27.52M	-$48.26M
Diluted EPS	-4.28	-3.16	-1.16	-0.49
Diluted Shares	4.22M	6.03M	23.71M	98.31M

IKT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$7.19M	$9.17M	$56.49M	$139.22M
Receivables	$39.88K	$0.00	—	—
Current Assets	$24.37M	$14.21M	$98.45M	$180.11M
Total Assets	$24.94M	$14.51M	$98.60M	$181.20M
Current Liabilities	$3.70M	$3.44M	$3.73M	$8.30M
Total Debt	$351.29K	$240.22K	$110.52K	$0.00
Total Liabilities	$3.90M	$3.53M	$3.73M	$8.30M
Retained Earnings	-$47.87M	-$66.90M	-$94.42M	-$142.68M
Shareholders' Equity	$21.04M	$10.98M	$94.87M	$172.90M
Working Capital	$20.68M	$10.77M	$94.72M	$171.81M

IKT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$17.35M	-$18.09M	-$19.15M	-$27.79M
Capital Expenditure	-$243.25K	-$14.24K	—	-$452.02K
Free Cash Flow	-$17.59M	-$18.10M	-$19.15M	-$28.24M
Depreciation & Amortisation	$6.72K	$177.40K	$26.27K	$60.50K
Stock-Based Compensation	$458.15K	$500.15K	$8.14M	$15.31M
Investing Cash Flow	-$16.01M	$11.66M	-$37.00M	$2.05M
Financing Cash Flow	-$204.77K	$8.41M	$103.48M	$108.46M
Net Change in Cash	-$33.56M	$1.98M	$47.33M	$82.73M

IKT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$10.51M	$5.27M	$7.65M	$6.36M	$10.84M
Selling, General & Admin	$5.25M	$5.92M	$5.61M	$6.77M	$7.38M
Operating Expenses	$15.76M	$11.19M	$13.26M	$13.13M	$18.22M
Operating Income	-$15.76M	-$11.19M	-$13.26M	-$13.13M	-$18.22M
EBITDA	-$15.75M	-$11.17M	-$13.24M	-$13.13M	-$18.22M
Pretax Income	-$13.68M	-$9.92M	-$11.93M	-$12.73M	-$16.38M
Net Income	-$13.68M	-$9.92M	-$11.93M	-$12.73M	-$16.38M
Diluted EPS	-0.15	-0.11	-0.13	—	-0.10
Diluted Shares	89.54M	90.01M	90.05M	—	172.31M

IKT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$73.44M	$77.74M	$38.27M	$139.22M	$49.57M
Current Assets	$94.16M	$88.79M	$78.54M	$180.11M	$172.18M
Total Assets	$94.28M	$88.85M	$79.59M	$181.20M	$173.33M
Current Liabilities	$8.55M	$8.80M	$6.70M	$8.30M	$5.71M
Total Debt	$74.77K	$37.94K	$0.00	$0.00	—
Total Liabilities	$8.55M	$8.80M	$6.70M	$8.30M	$5.71M
Retained Earnings	-$108.10M	-$118.01M	-$129.95M	-$142.68M	-$159.06M
Shareholders' Equity	$85.73M	$80.05M	$72.90M	$172.90M	$167.62M
Working Capital	$85.61M	$80.00M	$71.84M	$171.81M	$166.46M

IKT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.10M	-$5.57M	-$10.59M	-$7.52M	-$12.06M
Capital Expenditure	-$452.02K	—	—	—	—
Free Cash Flow	-$4.56M	-$5.57M	-$10.59M	-$7.52M	-$12.06M
Depreciation & Amortisation	$12.65K	$24.16K	$23.69K	$0.00	$0.00
Stock-Based Compensation	$2.04M	$4.21M	$4.53M	$4.53M	$5.56M
Investing Cash Flow	$21.05M	$9.84M	-$28.75M	-$98.85K	-$80.48M
Financing Cash Flow	$0.00	$31.77K	-$134.13K	$108.57M	$2.90M
Net Change in Cash	$16.95M	$4.30M	-$39.47M	$100.95M	-$89.65M

Market Snapshot

About

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing protein kinase inhibitors to modify the course of Parkinson's disease and related neurodegenerative disorders. The company's lead product candidate, IkT-148009, is designed to inhibit c-Abl, a protein kinase that has been implicated in the progression of Parkinson's disease by promoting the accumulation of toxic protein aggregates. Inhibikase is conducting clinical trials to evaluate IkT-148009's potential to slow or stop disease progression rather than just treating symptoms. The company represents a novel approach to addressing neurodegenerative diseases by targeting underlying disease mechanisms at the molecular level.